In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Brought to you by

BMS sells 15% of Mead through IPO that nets $684mm

18 Mar 2009

Executive Summary

Keeping up with plans to limit resources on its non-pharmaceutical assets, Bristol-Myers Squibb has sold about 15% of Mead Johnson Nutrition in an IPO. BMS netted $684mm from 30mm Mead shares at $24 each, the high end of the $21-24 anticipated range. In early February it had planned to offer 25mm shares.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Nutraceuticals
    • OTC, Consumer
Deal Status
  • Final
Deal Type
  • Financing
    • IPO
    • Spin-Off

Related Companies

UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By